1672.HK
ASCLETIS-B
HK$10.10
-0.49%
2026-06-10
About ASCLETIS-B
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
Key Fundamentals
Forward P/E
-37.43
EPS (TTM)
HK$-0.43
ROE
-18.5%
Revenue Growth (YoY)
-26.2%
Profit Margin
0.0%
Debt/Equity
0.27
Price/Book
4.64
Beta
0.40
Market Cap
HK$11.06B
Avg Volume (10D)
4.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$19.86
60D Low
HK$9.70
Avg Volume
2.5M
Latest Close
HK$10.10
Get breakout alerts for 1672.HK
Sign up for Breakout Scanner to receive daily notifications when 1672.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ASCLETIS-B (1672.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1672.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1672.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.